Table 3.
FISH characterization of prostate cancer specific molecular alterations (PTEN deletions top; ERG rearrangements bottom) in phenotypically diverse CTCs in patients with mCRPC
| Patient | Cell Type | PTEN evaluable cells | AR+ cells | PTEN heterozygous cells | PTEN homozygous cells | 1PTEN deletion cells |
|---|---|---|---|---|---|---|
| (n) | (%) | (n) | (n) | (%) | ||
| V4004* | Traditional | 7 | 14% | 2 | 0 | 29% |
| CK− | 0 | N/A | N/A | N/A | N/A | |
| Small | 0 | N/A | N/A | N/A | N/A | |
|
| ||||||
| V5035 | Traditional | 32 | 0% | 1 | 0 | 3% |
| CK− | 4 | 25% | 0 | 0 | 0% | |
| Small | 1 | 0% | 0 | 0 | 0% | |
|
| ||||||
| V5042* | Traditional | 11 | 36% | 0 | 4 | 37% |
| CK− | 9 | 44% | 1 | 4 | 56% | |
| Small | 2 | 0% | 0 | 0 | 0% | |
|
| ||||||
| V5131 | Traditional | 12 | 0% | 1 | 1 | 17% |
| CK− | 5 | 0% | 0 | 0 | 0% | |
| Small | 0 | N/A | N/A | N/A | N/A | |
|
| ||||||
| V5055 | Traditional | 13 | 0% | 0 | 0 | 0% |
| CK− | 0 | N/A | N/A | N/A | N/A | |
| Small | 0 | N/A | N/A | N/A | N/A | |
| Patient | Cell Type | ERG evaluable cells | AR+ cells | ERG 5′ deletion cells | ERG 5′/3′ split cells | 2ERG rearranged cells |
|---|---|---|---|---|---|---|
| (n) | (%) | (n) | (n) | (%) | ||
| V4048 | Traditional | 11 | 0%** | 0 | 0 | 0% |
| CK− | 0 | N/A | N/A | N/A | N/A | |
| Small | 0 | N/A | N/A | N/A | N/A | |
|
| ||||||
| V5025* | Traditional | 73 | 73% | 6 | 12 | 25% |
| CK− | 10 | 90% | 0 | 0 | 0% | |
| Small | 23 | 48% | 2 | 4 | 26% | |
|
| ||||||
| V5083 | Traditional | 35 | 63% | 4 | 7 | 31% |
| CK− | 2 | 100% | 0 | 1 | 50% | |
| Small | 3 | 0% | 0 | 0 | 0% | |
|
| ||||||
| V5085* | Traditional | 64 | 94% | 0 | 4 | 6% |
| CK− | 6 | 83% | 0 | 1 | 17% | |
| Small | 0 | N/A | N/A | N/A | N/A | |
|
| ||||||
| V5106 | Traditional | 9 | 56% | 0 | 3 | 33% |
| CK− | 1 | 100% | 0 | 1 | 100% | |
| Small | 0 | N/A | N/A | N/A | N/A | |
|
| ||||||
| 5131* | Traditional | 21 | 0% | 0 | 3 | 14% |
| CK− | 7 | 0% | 0 | 0 | N/A | |
| Small | 1 | 100% | 0 | 0 | N/A | |
FISH analysis for prostate cancer specific alterations was performed on selected patients. The percentage of CTCs (stratified by CTC type) with androgen receptor (AR) positivity by immunofluorescence (IF) is given for patients assessed for PTEN loss (top panel) or ERG rearrangement (bottom) by FISH. False positive PTEN HE and HO rate in white blood cells (WBCs) 2.5% (3/120 WBCs) and 0% (0/120 WBCs), respectively. False positive ERG 5′ deletion and 5′/3′ split rate 0% (0/220 WBCs) and 4.5% (10/220 WBCs), respectively.
Including both HE and HO cells.
Both 5′ deletion and 5′/3′ split cells.
Additional slides beyond the standard 2 slides were used for FISH evaluation.
3 cells were unevaluable for AR expression.